Cardio Diagnostics, Inc.

Company profile

About Cardio Diagnostics, Inc.

Cardio Diagnostics, Inc. is a precision medicine company that leverages epigenetics, genetics, and artificial intelligence to transform cardiovascular disease prevention and detection. The company operates a CLIA-certified clinical laboratory offering proprietary blood tests that assess coronary heart disease (CHD) through molecular biomarker analysis. Their flagship clinical solutions include Epi+Gen CHD™, which predicts three-year risk of coronary heart disease events with twice the sensitivity of conventional risk calculators, and PrecisionCHD™, which aids in CHD diagnosis and identifies patient-specific molecular drivers of disease. Both tests analyze targeted panels of epigenetic (DNA methylation) and genetic biomarkers using AI models to deliver personalized insights. The company's technology addresses critical gaps in traditional cardiovascular assessment, where 50% of CHD patients lack traditional risk factors and conventional risk calculators demonstrate only 39% average sensitivity. Beyond clinical testing, Cardio Diagnostics offers population health platforms and biopharma research solutions that transform complex molecular data into actionable intelligence. Their HeartRisk™ platform provides real-time population cardiovascular risk profiling, while CardioInnovate360™ supports biomarker discovery and clinical trial design for pharmaceutical partners. The company serves healthcare providers, health systems, payers, employers, and pharmaceutical companies, with state clinical laboratory licenses in California, Maryland, Pennsylvania, and Rhode Island. Their tests are prescription-only, FSA/HSA eligible, non-invasive, require no fasting or radiation, and are compatible with telemedicine delivery.

Company description · Cardio Diagnostics, Inc. official website